Xeploitrazole 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent indicated for the treatment of various systemic and superficial fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the conversion of lanosterol to ergosterol, a key component of fungal cell membranes. Disruption of ergosterol synthesis results in increased membrane permeability and ultimately fungal cell death. Xeploitrazole 200 Capsule is effective against infections caused by dermatophytes, yeasts including Candida species, and molds such as Aspergillus. It is commonly prescribed for conditions including blastomycosis, histoplasmosis, onychomycosis, and aspergillosis. The capsule formulation facilitates oral administration with improved bioavailability when taken with food. Dosage and duration of therapy depend on the type and severity of infection, and treatment should be guided by clinical response and laboratory findings. Caution is advised in patients with hepatic impairment, and potential drug interactions should be reviewed due to itraconazole’s inhibition of CYP3A4 enzymes. Adverse effects may include gastrointestinal disturbances, headache, and elevated liver enzymes. Regular monitoring of liver function tests is recommended during prolonged therapy. Xeploitrazole 200 Capsule should be used under medical supervision to ensure safe and effective antifungal treatment.